Why MDA-MB-231 Remains the Gold Standard for Triple-Negative Breast Cancer Research
Triple-negative breast cancer is, by any measure, one of oncology’s most stubborn problems. It accounts for roughly 15–20% of all breast cancer diagnoses worldwide, yet its defining feature — the absence of oestrogen receptor, progesterone receptor, and HER2 expression — means the targeted therapies that have transformed outcomes for other subtypes simply do not apply….
